PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33922540-4 2021 The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients. Dimethyl Fumarate 154-171 NAD(P)H quinone dehydrogenase 1 Homo sapiens 69-73 33803289-7 2021 The DMF treatment was associated with no changes in virus replication; higher expressions of the antioxidant enzymes NQO1, GPX1, and HO-1 in the brain and PRDX1 and HO-2 in the spleen; lower levels of 8-OHdG and 3NT; a lower optical redox ratio. Dimethyl Fumarate 4-7 NAD(P)H quinone dehydrogenase 1 Homo sapiens 117-121 34426902-10 2021 Moreover, the expression of HO-1 and NQO-1 was upregulated in hASCs pretreated with DMF which confirms the activation of the Nrf2 pathway. Dimethyl Fumarate 84-87 NAD(P)H quinone dehydrogenase 1 Homo sapiens 37-42 33922540-4 2021 The results suggest that polymorphisms detected in the GSTP1, ITGA4, NQO1, AKT1, and GP6 genes, for treatment with natalizumab, ZMIZ1, for fingolimod and dimethyl fumarate, ADA, for cladribine, and NOX3, for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients. Dimethyl Fumarate 208-225 NAD(P)H quinone dehydrogenase 1 Homo sapiens 69-73 29928650-6 2018 In a subgroup of 28 patients with completely available clinical data, individuals with higher levels of the NRF2 target gene NAD(P)H quinone dehydrogenase 1 (NQO1) 4-6 weeks after DMF therapy initiation were more likely to achieve no evidence of disease activity status 1 year later. Dimethyl Fumarate 180-183 NAD(P)H quinone dehydrogenase 1 Homo sapiens 125-156 29928650-6 2018 In a subgroup of 28 patients with completely available clinical data, individuals with higher levels of the NRF2 target gene NAD(P)H quinone dehydrogenase 1 (NQO1) 4-6 weeks after DMF therapy initiation were more likely to achieve no evidence of disease activity status 1 year later. Dimethyl Fumarate 180-183 NAD(P)H quinone dehydrogenase 1 Homo sapiens 158-162 28156185-7 2017 RESULTS: DMF and MMF induced NQO1 and HO1 gene expression in ex vivo-stimulated PBMCs, DMF being the more potent inducer. Dimethyl Fumarate 9-12 NAD(P)H quinone dehydrogenase 1 Homo sapiens 29-33 28156185-8 2017 Induction of NQO1 occurred at lower DMF concentrations compared to that of HO1. Dimethyl Fumarate 36-39 NAD(P)H quinone dehydrogenase 1 Homo sapiens 13-17 28156185-9 2017 In DMF-treated patients, a statistically significant induction of NQO1 was observed relative to baseline and compared to placebo. Dimethyl Fumarate 3-6 NAD(P)H quinone dehydrogenase 1 Homo sapiens 66-70 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 13-29 NAD(P)H quinone dehydrogenase 1 Homo sapiens 138-170 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 13-29 NAD(P)H quinone dehydrogenase 1 Homo sapiens 172-176 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 31-34 NAD(P)H quinone dehydrogenase 1 Homo sapiens 138-170 25009787-2 2014 We tested if dimethylfumarate (DMF), an anti-psoriasis drug, could inhibit abnormal vascular remodeling via NF-E2-related factor 2 (Nrf2)-NAD(P)H quinone oxidoreductase 1 (NQO1) activity. Dimethyl Fumarate 31-34 NAD(P)H quinone dehydrogenase 1 Homo sapiens 172-176 25009787-10 2014 In conclusion, DMF prevented abnormal proliferation in VSMCs by G1 cell cycle arrest via p21 upregulation driven by Nrf2 and p53 activity, and had a beneficial effect on TNF-alpha-induced apoptosis and dysfunction in endothelial cells through Nrf2-NQO1 activity suggesting that DMF might be a therapeutic drug for patients with vascular disease. Dimethyl Fumarate 15-18 NAD(P)H quinone dehydrogenase 1 Homo sapiens 248-252 15655414-1 2005 We compared the cytotoxicity of the bioreductive antitumor agents mitomycin C (MMC) and streptonigrin (SN) with or without the DT-diaphorase (DTD) inducer dimethyl fumarate (DMF) in four human glioblastoma cell lines with the conventional chemotherapeutic agent, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Dimethyl Fumarate 155-172 NAD(P)H quinone dehydrogenase 1 Homo sapiens 127-140 24076006-6 2013 We show that dimethylfumarate (DMF) and its primary metabolite monomethylfumarate (MMF) induce the expression of the Nrf2/NQO1 pathway in endothelial cells. Dimethyl Fumarate 13-29 NAD(P)H quinone dehydrogenase 1 Homo sapiens 122-126 24076006-6 2013 We show that dimethylfumarate (DMF) and its primary metabolite monomethylfumarate (MMF) induce the expression of the Nrf2/NQO1 pathway in endothelial cells. Dimethyl Fumarate 31-34 NAD(P)H quinone dehydrogenase 1 Homo sapiens 122-126 15877230-7 2005 Dimethyl fumarate and sulforaphane treatment increased NQO1 activity by 1.4- to 2.8-fold and resulted in a significant enhancement of the antitumor activity of mitomycin C, but not of RH1. Dimethyl Fumarate 0-17 NAD(P)H quinone dehydrogenase 1 Homo sapiens 55-59 15467770-3 2004 CD-1 nude mice were implanted with HCT116 cells, and fed control diet or diet containing 0.3% of the NQO1 inducer, dimethyl fumarate (DMF). Dimethyl Fumarate 115-132 NAD(P)H quinone dehydrogenase 1 Homo sapiens 101-105 15467770-3 2004 CD-1 nude mice were implanted with HCT116 cells, and fed control diet or diet containing 0.3% of the NQO1 inducer, dimethyl fumarate (DMF). Dimethyl Fumarate 134-137 NAD(P)H quinone dehydrogenase 1 Homo sapiens 101-105 10376975-5 1999 DT-diaphorase was induced by many dietary inducers, including propyl gallate, dimethyl maleate, dimethyl fumarate and sulforaphane. Dimethyl Fumarate 96-113 NAD(P)H quinone dehydrogenase 1 Homo sapiens 0-13